Severe hypoglycaemia developed seven months after a bone marrow transplantation in a child with severe combined immunodeficiency. His serum exerted potent insulin-like activity: (a) it stimulated insulin receptor autophosphorylation and kinase activity in cell-free systems, this effect being additive to insulin; (b) it increased glucose transport in isolated soleus muscle. These insulin-like effects were due to immunoglobulins against the insulin receptor. Indeed, the patient serum immunoprecipitated human or murine insulin receptors from different tissues and inhibited insulin binding to receptor on human IM-9 lymphocytes. After corticoids and immunosuppressive therapy by azathioprine, the patient hypoglycaemic episodes disappeared, and concomitantly, the antibodies to insulin receptor were no longer detected, as judged by both immunoprecipitation of insulin receptor and stimulation of glucose transport.
Subject
A seven month old child (P.S.) had severe combined immunodeficiency characterised by the absence of T lymphocytes with normal B lymphocyte counts [7] . He received a T-cell depleted HLA partially incompatible bone marrow graft from his mother without prior conditioning. T-cell depletion was performed using the CAMPATH I monoclonal antibody [8] and human complement. HLA incompatibility concerned one full HLA haplotype [9] . No graft versus host disease (GVHD) prophylaxis was given. There has been no detectable complication of the bone marrow graft and five months after the transplantation, his T and B cell immunodeficiency was corrected, During the 7th month post transplant, a severe hypoglycaemic state developed, with attacks leading to convulsions or coma. There was no ketosis, insulin levels were low and serum cortisol level was normal. There were no antibodies against insulin or pancreatic islet cells. Simultaneously, other autoimmune manifestations occurred including haemolytic anemia, thrombocytopenia, and neutropenia. Furthermore, liver enzymes were increased without manifestations of hepatocellular failure. A liver biopsy showed an histologic aspect of active chronic hepatitis. No other serum antibodies were detected including antibodies to endocrine glands. The prevention of hypoglycaemia necessitated regular carbohydrate feeding. Corticotherapy (prednisone, 2 mg/kg/24 tl) was begun to control the autoimmune manifestations. Azathioprine (2 mg/kg/24 h) was added in a second phase because of the chronic hepatitis. Following treatment, the hypoglycaemic episodes disappeared progressively in 15 days.
Insulin binding inhibition assays
Binding of 125I-insulin was measured on human IM-9 lymphocytes or on fibroblasts transfected with human insulin receptor cDNA as previously described [10] . Membranes were prepared from rat liver [11] or human placenta [10] and insulin binding measured as described [11] . Insulin receptors were solubilised from the same sources and insulin binding measured as follows: t0 ~tl of receptor preparations were incubated in 150 gl Hepes (50retool/I, pH 7.4), NaC1 (150retool/I) buffer in presence of P.S. or control serum at various dilutions. Following this incubation (3 h, 15~ 125I-insulin binding was measured after 2 h at 15~ as described [12] .
Insulin receptor immunoprecipitation

R e s u l t s
Human insulin receptors from HIRc cells (rat embryo fibroblasts transfected with human insulin receptor cDNA [13] ) and receptors from rat liver or mouse skeletal muscle were partially purified by Triton X-100 solubilisation and chromatography on wheat germ agglutinin agarose (WGA) [14] . The insulin receptor [~-subunit was labelled by autophosphorylation as follows: WGA eluates were incubated for 120min at 20~ with insulin (llxmol/1). The phosphorylation reaction was initiated by addition of [y-32-P] ATP (15 ~mol/l), MnC12 (4 mmol/1), MgC12 (8 mmol/1) [15] . After 15 min at 20~ the reaction was stopped by adding ice-cold stopping solution (NaF 100 mmol/l, EDTA 20 mmol/1, final concentrations) and phosphoproteins were immunoprecipitated by P.S. serum (1/20 to 1/100 dilution) or control serum (1/20 dilution) for 12 h at 4~ followed by addition of protein A. The pellets containing the immunoadsorbed proteins were washed, and subsequently analysed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) according to Laemmli [16] .
Insulin receptor autophosphorylation and kinase activity
The ability of P. S. serum to stimulate insulin receptor autophosphorylation was studied by incubation of receptor preparations with serum in absence or presence of insulin for 2 h at 22 ~ C. Phosphorylation was then carried out as described above and samples were directly analysed by SDS/PAGE.
The effect of serum on insulin receptor kinase activity was measured as follows: WGA preparations were pre-incubated with serum and/or insulin for 2 h at 15 ~ C. The substrate (poly[glutamatetyrosine, 4-1], 0.25 mg/ml) was added for an additional 30 min. Phosphorylation was then performed as previously described [171.
Preparation of purified immunoglobulins Evidence for the presence of antibodies to insulin receptor
The clinical picture of hypoglycaemic episodes without hyperinsulinaemia and with ketone levels below the limit of detection in a context of autoimmune disease suggested that the patient serum could contain antibodies to insulin receptor. We first tested P. S. serum for its ability to immunoprecipitate human insulin receptors, whose [~-subunit was labelled by autophosphorylation with [7-32P] ATP. As shown in Figure 1 , P.S. serum was able to precipitate a significant amount of labelled receptors in a dose-dependent manner. At a 1/50 dilution, it was as potent as serum from patient B7 (a gift of Dr P Go,rden, NIH, Bethesda, Md, USA) used at a 1/150 dilution. This B7-patient suffered from a severe insulin resistance due to antibodies against the insulin receptor [2] . P.S. antibody was able to recognise insulin receptors not only from human sources ( Fig. 1 ), but also from mouse skeletal muscle and from rat liver (data not shown). This antibody was specific for insulin receptor, since it did not recognise the EGF receptor also present in rat liver preparations (data not shown).
Serum from P. S. was then examined for its ability to interfere with insulin binding to receptor. No inhibition was observed with solubilised receptors or plasma membranes. In contrast, the patient's serum was able to compete with 125I-labelled insulin binding to human IM-9 lymphocytes, half maximal inhibition being obtained at a 1/50 dilution (Table 1) . Similar inhibition of insulin binding was observed with cells transfected with
Immunoglobulins were purified as follows: serum was incubated for 4 h at 4~ with protein A sepharose. Following washing with 100 vol of Hepes (30 mmol/1, pH 7.4), 30 mmol/l NaC1 buffer, immunoglobulins fractions were eluted with citrate buffer (0.t mol/1, pH 3.5) and rapidly neutralised with Tris buffer (1 mol/1, pH 8). Fractions containing proteins were dialysed, concentrated by ultrafiltration and then used for receptor immunoprecipitation and autophosphorylation as described above.
Bioassay of insulin-like activity
Insulin-like activity of the patient's serum was tested by its ability to stimulate glucose transport in mouse skeletal muscle as follows. Soleus muscles were isolated and pre-incubated for 90 rain at 37~ with a normal serum or the patient's serum as previously described [18] . Thereafter, muscles were washed twice for 5 min at 20~ to remove all serum factors not tightly bound. Muscles were then incubated for 15 min at 37 ~ C, in presence or absence of insulin, with 1-[14C]-2-deoxyglucose (0.5 mmol/1, 0.5 lxCi/ml), deoxyglucose uptake being an index of glucose transport and phosphorylation. Muscles were washed and radioactivity counted [18] .
Statistical analysis
Statistical significance in incubated muscles experiments was assessed using Student's t test for unpaired comparisons [19] . Human IM-9 lymphocytes (106 cells/ml) were pre-incubated for 120 min at 30~ with P.S. or control serum at indicated dilution. Thereafter, ~25I-labelled insulin was added for 180 rain at 15~ At the end of incubation, cells were centrifuged, washed and the radioactivity bound to cells counted. Results of binding obtained with P.S. serum are expressed as a percentage of the binding observed with control serum at the same dilution human insulin receptor cDNA (data not shown). Taken together, our results indicate that P.S. serum contained antibodies which were able to immunoprecipitate insulin receptors and to inhibit insulin binding in intact cells.
Insulinomimetic effect of the antibodies to receptor
To explain the hypoglycaemia of P. S., we next searched for insulin-like activities of these antibodies. We first studied the ability of this serum to stimulate glucose uptake in skeletal muscle, an important tissue for glucose utilisation. As shown in Figure 2 , patient serum markedly stimulated deoxyglucose uptake in basal condition (no insulin). This insulinomimetic effect was very pronounced since, at a 1/50 dilution, its effect was similar to that obtained with a submaximal insulin concentration. This stimulatory action could very likely not be accounted for by insulin or serum factors other than 169 antibodies to insulin receptor, since it prevailed after two washes of muscles and measurement of deoxyglucose uptake being performed in serum-free medium. The effects of serum and insulin were additive, but only when the hormone was used at a submaximal concentration.
The insulin receptor [~-subunit is a tyrosine kinase whose autophosphorylation is stimulated by the hormone. A large body of evidence clearly indicates that this receptor enzymatic activity plays an essential role in insulin's biological actions [20, 21] . It was thus of interest to investigate whether the patient serum was able to activate the insulin receptor kinase on solubilised receptors. As shown in Figure 3 , left panel, P.S. serum obtained during the hypoglycaemic period increased 32p incorporation in the 95K insulin receptor D, E) . Further, the effects of antibodies and insulin were additive (lane F). Similar results were obtained when the tyrosine kinase activity towards a synthetic copolymer of glutamate-tyrosine was measured (Fig. 3, fight panel) . P. S. serum alone was as potent as insulin in stimulating this activity, and the effects of both agents were additive.
To substantiate the nature of the serum factor which was responsible for the observed effects, immunoglobulins fractions were purified from control serum and P. S. serum by protein A chromatography. The fraction eluted from the patient serum was able to immunopre-cipitate phosphorylated insulin receptor, while the control immunoglobulins were without effect (Fig.4, left  panel) . More important, this fraction was also able to stimulate insulin receptor autophosphorylation in a dose-dependent fashion (Fig.4, fight panel) . These results indicate that the serum effects could be assigned to immunoglobulins of the IgG class.
Antibodies to the insulin receptor are responsible for the patient's hypoglycaemia
Analysis of serum samples obtained at different periods of the illness substantiated the role of the antibodies in the pathogenesis of the hypoglycaemic syndrome. First, a serum obtained from P.S. three months after the transplantation, before any sign of glycaemic disorder, fail to induce immunoprecipitation or autophosphorylation of insulin receptors. More important, these activities disappeared after three weeks of prednisone therapy and the biological evolution of P. S. serum coincided with a marked clinical improvement of his glycaemic control (Fig. 5) . Moreover, the causal relationship between hypoglycaemia and antibodies was further established by the evolution of the insulin-like effect of patient serum on glucose uptake in muscle. As shown in Figure 2 , P.S. serum obtained three weeks after the beginning of corticotherapy was no longer able to stimulate 2-deoxyglucose uptake in muscle.
D i s c u s s i o n
We describe here the appearance of antibodies to insulin receptor in a young immunodeficient child, who had received a bone marrow transplantation. The key interest in this case report comes from the fact that several biological and clinical features differed markedly from those described previously. The vast majority of autoantibodies to insulin receptor have been found in patients with insulin resistance [2] . In contrast to those patients, P.S. developed profound hypoglycaemia explained by the very potent insulin-like activity of his antibodies. Indeed, at a 1/20 dilution, his serum was as potent as insulin in activating insulin receptor autophosphorylation and tyrosine kinase activity towards a synthetic substrate in a cell-free system (Fig. 3) . Further, addition of insulin was still able to increase the level of insulin receptor kinase activity already obtained with P.S. serum alone.,. Such additive effect of insulin and antibodies on insulin receptor had not been reported with autoantibodies from patients [6] but has been reported only in the case of a polyclonal antibody raised in rabbit against a purified insulin receptor preparation [10] . Our observation, on solubilised receptors, of an antibody with additive effect to maximally effective insulin concentrations without inhibition of insulin binding, suggests that this antibody binds to the receptor at a locus distinct from the hormone binding site. Its interaction with receptor is such that it leads to a powerful activation of the receptor tyrosine kinase. The decrease in insulin binding found solely in intact cells would indicate that an active cellular process is involved in this loss of binding.
When the effect of P. S. serum was tested in skeletal muscle, an important organ for insulin action and glucose utilisation, a marked insulin-like activity was observed on glucose uptake and phosphorylation. At maximally effective concentrations, the effects of insulin and antibodies were not additive on glucose uptake, suggesting that the limiting step was glucose transport and not the stimulation of kinase activity. A similar observation has been reported for insulin-induced effects in cells expressing a 100-1000 increase in receptor number. Thus, only the sensitivity to insulin was increased, while the maximal biological response to the hormone was unchanged [22, 23] .
The striking parallelism between the evolution of the presence of antibodies to insulin receptor and the glycaemic episodes demonstrates the pathogenetic role of these antibodies in the clinical syndrome. Indeed, when hypoglycaemia was the most severe, antibody titer was maximal. Similarly after three weeks of treatment, antibody titer and insulin-like effects of serum progressively decreased in vitro, concomitantly with an improvement of the glycaemic status.
At present, the mechanism responsible for occurrence of antibodies to insulin receptor remains a matter of speculation. Evidence for selective molecular interactions between insulin receptors and the major histocompatibility system antigens has been reported in human B lymphocytes [23] . Furthermore, polymorphism at the insulin receptor locus has been found [24] . It is thus conceivable that the insulin receptors of mother (the graft donor) and child are sufficiently different to lead to the generation of alloantibodies. Currently, we are investigating whether the antibodies present in P.S. serum are produced by the child's or the mother's lymphocytes. However, since the antibodies to insulin receptor appeared together with several autoantibodies, autoimmunity is the most likely hypothesis. Autoimmune manifestations have been described post bone marrow transplantation in patients with chronic graft versus host disease [26-291, but not uncommonly does autoimmunity appear to be independent of chronic GVHD in patients having received HLA incompatible bone marrow transplantation (unpublished observation). Note that P.S. had no clear manifestations of chronic GVHD. This autoimmunity process could also be related to the autoreactivity of engrafted T lymphocytes towards own HLA class II antigen potentially able to give non specific polyclonal help for B lymphocytes.
The results reported in this paper re-inforce the idea that antibodies to insulin receptor should be considered in the differential diagnosis of patients with idiopathic 171 hypoglycaemia, particularly when autoimmune manifestations are present. The search for antibodies should comprise a comprehensive series of detection methods including immunoprecipitation of receptors, hormone binding assays in different systems, and biological assays. Indeed, some patients might develop antibodies to insulin receptor which are not directed against the insulin binding site but can, nevertheless, activate the receptor kinase and induce insulin-like effects as also described for some polyclonal or monoclonal antibodies [10, 301. 
